Buch, Englisch, Band 8, 262 Seiten, Previously published in hardcover, Format (B × H): 155 mm x 235 mm, Gewicht: 429 g
Buch, Englisch, Band 8, 262 Seiten, Previously published in hardcover, Format (B × H): 155 mm x 235 mm, Gewicht: 429 g
Reihe: Topics in Medicinal Chemistry
ISBN: 978-3-642-43955-1
Verlag: Springer
Michael D. Wendt
Protein-Protein Interactions as Drug Targets
Shaomeng Wang , Yujun Zhao , Denzil Bernard , Angelo Aguilar , Sanjeev Kumar
Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics
Kurt Deshayes , Jeremy Murray , Domagoj Vucic
The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer
John F. Kadow , David R. Langley , Nicholas A. Meanwell , Michael A. Walker , Kap-Sun Yeung , Richard Pracitto
Protein-Protein Interaction Targets to Inhibit HIV-1 Infection
Nicholas A. Meanwell , David R. Langley
Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion – a Focus on Respiratory Syncytial Virus
Andrew B. Mahon , Stephen E. Miller , Stephen T. Joy , Paramjit S. Arora
Rational Design Strategies for Developing Synthetic Inhibitors of Helical Protein Interfaces
Michael D. Wendt
The Discovery of Navitoclax, a Bcl-2 Family Inhibitor
Zielgruppe
Research
Autoren/Hrsg.
Fachgebiete
- Naturwissenschaften Biowissenschaften Proteinforschung
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie
- Naturwissenschaften Chemie Organische Chemie Biochemie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Biochemie (med.)
- Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)
- Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie
Weitere Infos & Material
Protein-Protein Interactions as Drug Targets.- Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics.- The Development of Small-Molecule IAP Antagonists for the Treatment of Cancer.- Protein-Protein Interaction Targets to Inhibit HIV-1 Infection.- Inhibitors of Protein-Protein Interactions in Paramyxovirus Fusion – a Focus on Respiratory Syncytial Virus.- Rational Design Strategies for Developing Synthetic Inhibitors of Helical Protein Interfaces.- The Discovery of Navitoclax, a Bcl-2 Family Inhibitor.
